Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MYB | P10242 | 6/20 | 0.48 |
| ▸ | TLR4 | O00206 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253805 | 0.93 | SMN1; SMN2 (0.45) | MAPTGAAPOLBTDP1L3MBTL1 | |
| SCHEMBL4252566 | 0.90 | POLB (0.55) | MAPTGAAPOLBTDP1L3MBTL1 | |
| SCHEMBL4256982 | 0.89 | MYB (0.61) | MAPTGAAPOLBTDP1L3MBTL1 | |
| SCHEMBL4249750 | 0.88 | MYB (0.50) | MAPTGAAPOLBTDP1L3MBTL1 | |
| SCHEMBL4249281 | 0.87 | POLB (0.62) | MAPTGAAPOLBTDP1L3MBTL1 | |
| SCHEMBL4256898 | 0.87 | MAPT (0.64) | MAPTGAAPOLBTDP1L3MBTL1 | |
| SCHEMBL4259239 | 0.87 | AKR1C3 (0.59) | MAPTMYBAKR1C3AKR1C1 | |
| SCHEMBL4249636 | 0.85 | POLB (0.54) | MAPTGAAPOLBTDP1L3MBTL1 | |
| SCHEMBL4255338 | 0.84 | SMN1; SMN2 (0.47) | MAPTPOLBMEN1KMT2AKDM4E | |
| SCHEMBL4252508 | 0.83 | TUBB4A (0.53) | MAPTGAAPOLBTDP1MYB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349864-B2 | Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349864-B2 | Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349864-B2 | Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION | 2009-10-01 | — | — | US | disclosed |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION | 2009-10-01 | — | — | US | disclosed |
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | NEW MEXICO TECHNICAL RESEARCH FOUNDATION | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247566-A1 | Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof | BAX, CASP3, CASP7 | MAPT 3099/4885GAA 3043/4885POLB 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.